-
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
넶28 2025-01-22 -
Tirzapatide approved by FDA as first sleep apnea medication
FDA has approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity.
넶34 2025-01-21 -
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
넶8 2025-01-22 -
Icotrokinra: New treatment for moderate to severe plaque psoriasis
Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias
넶10 2025-01-22
